Biotage Future Growth
Future criteria checks 3/6
Biotage is forecast to grow earnings and revenue by 19.4% and 10.9% per annum respectively. EPS is expected to grow by 18.8% per annum. Return on equity is forecast to be 9.9% in 3 years.
Key information
19.4%
Earnings growth rate
18.8%
EPS growth rate
| Life Sciences earnings growth | 44.8% |
| Revenue growth rate | 10.9% |
| Future return on equity | 9.9% |
| Analyst coverage | Low |
| Last updated | 03 May 2024 |
Recent future growth updates
Revenue Beat: Biotage AB (publ) Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates
Apr 28
Biotage AB (publ) Just Beat EPS By 53%: Here's What Analysts Think Will Happen Next
Apr 08Biotage AB (publ) Just Recorded A 53% EPS Beat: Here's What Analysts Are Forecasting Next
Feb 18Recent updates
Revenue Beat: Biotage AB (publ) Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates
Apr 28Biotage's (STO:BIOT) Dividend Will Be SEK1.60
Apr 17Biotage AB (publ) Just Beat EPS By 53%: Here's What Analysts Think Will Happen Next
Apr 08Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60
Apr 03Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60
Mar 04Weak Statutory Earnings May Not Tell The Whole Story For Biotage (STO:BIOT)
Feb 22Subdued Growth No Barrier To Biotage AB (publ) (STO:BIOT) With Shares Advancing 32%
Feb 21Biotage AB (publ) Just Recorded A 53% EPS Beat: Here's What Analysts Are Forecasting Next
Feb 18Biotage (STO:BIOT) Has A Pretty Healthy Balance Sheet
Feb 08Investors Still Waiting For A Pull Back In Biotage AB (publ) (STO:BIOT)
Jan 07At kr124, Is It Time To Put Biotage AB (publ) (STO:BIOT) On Your Watch List?
Dec 08Estimating The Intrinsic Value Of Biotage AB (publ) (STO:BIOT)
Oct 27Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?
Jul 12An Intrinsic Calculation For Biotage AB (publ) (STO:BIOT) Suggests It's 26% Undervalued
Jun 08Biotage (STO:BIOT) Ticks All The Boxes When It Comes To Earnings Growth
May 24Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's
Apr 05These 4 Measures Indicate That Biotage (STO:BIOT) Is Using Debt Safely
Mar 12Is It Too Late To Consider Buying Biotage AB (publ) (STO:BIOT)?
Feb 21Are Biotage AB (publ) (STO:BIOT) Investors Paying Above The Intrinsic Value?
Jan 06Biotage (STO:BIOT) Seems To Use Debt Rather Sparingly
Dec 03Is Now The Time To Look At Buying Biotage AB (publ) (STO:BIOT)?
Oct 27Estimating The Fair Value Of Biotage AB (publ) (STO:BIOT)
Oct 07Biotage (STO:BIOT) Could Easily Take On More Debt
Sep 03Is There Now An Opportunity In Biotage AB (publ) (STO:BIOT)?
Jul 10A Look At The Fair Value Of Biotage AB (publ) (STO:BIOT)
Jun 25Do Biotage's (STO:BIOT) Earnings Warrant Your Attention?
May 28Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's
Apr 23Biotage (STO:BIOT) Is Paying Out A Larger Dividend Than Last Year
Mar 29Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?
Mar 14Is It Time To Consider Buying Biotage AB (publ) (STO:BIOT)?
Feb 28Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's
Feb 13A Look At The Fair Value Of Biotage AB (publ) (STO:BIOT)
Jan 23Is Biotage (STO:BIOT) A Risky Investment?
Dec 10Is Now The Time To Put Biotage (STO:BIOT) On Your Watchlist?
Nov 03Biotage (STO:BIOT) Has A Rock Solid Balance Sheet
Aug 17Is Now The Time To Put Biotage (STO:BIOT) On Your Watchlist?
Jul 24Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,678 | 464 | 622 | 757 | 3 |
| 12/31/2025 | 2,387 | 357 | 416 | 542 | 3 |
| 12/31/2024 | 2,175 | 277 | 303 | 421 | 2 |
| 3/31/2024 | 1,981 | 236 | 268 | 381 | N/A |
| 12/31/2023 | 1,862 | 246 | 193 | 284 | N/A |
| 9/30/2023 | 1,603 | 189 | 183 | 264 | N/A |
| 6/30/2023 | 1,555 | 216 | 182 | 258 | N/A |
| 3/31/2023 | 1,541 | 240 | 220 | 295 | N/A |
| 12/31/2022 | 1,566 | 268 | 271 | 341 | N/A |
| 9/30/2022 | 1,524 | 240 | 285 | 346 | N/A |
| 6/30/2022 | 1,428 | 228 | 285 | 338 | N/A |
| 3/31/2022 | 1,337 | 216 | 290 | 342 | N/A |
| 12/31/2021 | 1,232 | 205 | 297 | 353 | N/A |
| 9/30/2021 | 1,188 | 203 | 273 | 336 | N/A |
| 6/30/2021 | 1,145 | 187 | 256 | 321 | N/A |
| 3/31/2021 | 1,096 | 174 | 222 | 286 | N/A |
| 12/31/2020 | 1,092 | 175 | 218 | 279 | N/A |
| 9/30/2020 | 1,083 | 149 | 213 | 268 | N/A |
| 6/30/2020 | 1,103 | 179 | 221 | 274 | N/A |
| 3/31/2020 | 1,131 | 201 | 211 | 260 | N/A |
| 12/31/2019 | 1,101 | 187 | 166 | 212 | N/A |
| 9/30/2019 | 1,047 | 196 | 145 | 187 | N/A |
| 6/30/2019 | 997 | 173 | 112 | 158 | N/A |
| 3/31/2019 | 951 | 170 | 94 | 139 | N/A |
| 12/31/2018 | 911 | 168 | 108 | 155 | N/A |
| 9/30/2018 | 865 | 175 | 120 | 170 | N/A |
| 6/30/2018 | 811 | 162 | 104 | 149 | N/A |
| 3/31/2018 | 771 | 148 | 123 | 168 | N/A |
| 12/31/2017 | 748 | 139 | N/A | 169 | N/A |
| 9/30/2017 | 738 | 122 | N/A | 145 | N/A |
| 6/30/2017 | 728 | 118 | N/A | 145 | N/A |
| 3/31/2017 | 694 | 105 | N/A | 131 | N/A |
| 12/31/2016 | 668 | 93 | N/A | 139 | N/A |
| 9/30/2016 | 657 | 96 | N/A | 130 | N/A |
| 6/30/2016 | 640 | 87 | N/A | 133 | N/A |
| 3/31/2016 | 625 | 78 | N/A | 133 | N/A |
| 12/31/2015 | 611 | 73 | N/A | 120 | N/A |
| 9/30/2015 | 580 | 83 | N/A | 116 | N/A |
| 6/30/2015 | 549 | 75 | N/A | 98 | N/A |
| 3/31/2015 | 521 | 75 | N/A | 94 | N/A |
| 12/31/2014 | 490 | 65 | N/A | 81 | N/A |
| 9/30/2014 | 474 | 53 | N/A | 72 | N/A |
| 6/30/2014 | 459 | 49 | N/A | 70 | N/A |
| 3/31/2014 | 455 | 46 | N/A | 52 | N/A |
| 12/31/2013 | 445 | 41 | N/A | 57 | N/A |
| 9/30/2013 | 437 | 37 | N/A | 66 | N/A |
| 6/30/2013 | 441 | 33 | N/A | 64 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BIOT's forecast earnings growth (19.4% per year) is above the savings rate (1%).
Earnings vs Market: BIOT's earnings (19.4% per year) are forecast to grow faster than the Swedish market (13.7% per year).
High Growth Earnings: BIOT's earnings are forecast to grow, but not significantly.
Revenue vs Market: BIOT's revenue (10.9% per year) is forecast to grow faster than the Swedish market (1.7% per year).
High Growth Revenue: BIOT's revenue (10.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BIOT's Return on Equity is forecast to be low in 3 years time (9.9%).